Table of Contents

2019-2024 Global Vaccine Adjuvants Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Vaccine Adjuvants Consumption 2014-2024
  • 2.1.2 Vaccine Adjuvants Consumption CAGR by Region
• 2.2 Vaccine Adjuvants Segment by Type
  • 2.2.1 Oral
  • 2.2.2 Subcutaneous
  • 2.2.3 Intramuscular
  • 2.2.4 Others
• 2.3 Vaccine Adjuvants Consumption by Type
  • 2.3.1 Global Vaccine Adjuvants Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Vaccine Adjuvants Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Vaccine Adjuvants Sale Price by Type (2014-2019)
• 2.4 Vaccine Adjuvants Segment by Application
  • 2.4.1 Veterinary Vaccine Adjuvants (Research Applications, Commercial Applications)
  • 2.4.2 Human Vaccine Adjuvants (Research Applications, Commercial Applications)
• 2.5 Vaccine Adjuvants Consumption by Application
  • 2.5.1 Global Vaccine Adjuvants Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Vaccine Adjuvants Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Vaccine Adjuvants Sale Price by Application (2014-2019)

3 Global Vaccine Adjuvants by Players

• 3.1 Global Vaccine Adjuvants Sales Market Share by Players
  • 3.1.1 Global Vaccine Adjuvants Sales by Players (2017-2019)
  • 3.1.2 Global Vaccine Adjuvants Sales Market Share by Players (2017-2019)
• 3.2 Global Vaccine Adjuvants Revenue Market Share by Players
  • 3.2.1 Global Vaccine Adjuvants Revenue by Players (2017-2019)
  • 3.2.2 Global Vaccine Adjuvants Revenue Market Share by Players (2017-2019)
• 3.3 Global Vaccine Adjuvants Sale Price by Players
• 3.4 Global Vaccine Adjuvants Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Vaccine Adjuvants Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Vaccine Adjuvants Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Vaccine Adjuvants by Regions

• 4.1 Vaccine Adjuvants by Regions
  • 4.1.1 Global Vaccine Adjuvants Consumption by Regions
  • 4.1.2 Global Vaccine Adjuvants Value by Regions
• 4.2 Americas Vaccine Adjuvants Consumption Growth
• 4.3 APAC Vaccine Adjuvants Consumption Growth
• 4.4 Europe Vaccine Adjuvants Consumption Growth
• 4.5 Middle East & Africa Vaccine Adjuvants Consumption Growth

5 Americas

• 5.1 Americas Vaccine Adjuvants Consumption by Countries
  • 5.1.1 Americas Vaccine Adjuvants Consumption by Countries (2014-2019)
  • 5.1.2 Americas Vaccine Adjuvants Value by Countries (2014-2019)
• 5.2 Americas Vaccine Adjuvants Consumption by Type
• 5.3 Americas Vaccine Adjuvants Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Vaccine Adjuvants Consumption by Countries
  • 6.1.1 APAC Vaccine Adjuvants Consumption by Countries (2014-2019)
  • 6.1.2 APAC Vaccine Adjuvants Value by Countries (2014-2019)
• 6.2 APAC Vaccine Adjuvants Consumption by Type
• 6.3 APAC Vaccine Adjuvants Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Vaccine Adjuvants by Countries
  • 7.1.1 Europe Vaccine Adjuvants Consumption by Countries (2014-2019)
  • 7.1.2 Europe Vaccine Adjuvants Value by Countries (2014-2019)
• 7.2 Europe Vaccine Adjuvants Consumption by Type
• 7.3 Europe Vaccine Adjuvants Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Vaccine Adjuvants by Countries
  • 8.1.1 Middle East & Africa Vaccine Adjuvants Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Vaccine Adjuvants Value by Countries (2014-2019)
• 8.2 Middle East & Africa Vaccine Adjuvants Consumption by Type
• 8.3 Middle East & Africa Vaccine Adjuvants Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Vaccine Adjuvants Distributors
• 10.3 Vaccine Adjuvants Customer

11 Global Vaccine Adjuvants Market Forecast

• 11.1 Global Vaccine Adjuvants Consumption Forecast (2019-2024)
• 11.2 Global Vaccine Adjuvants Forecast by Regions
  • 11.2.1 Global Vaccine Adjuvants Forecast by Regions (2019-2024)
  • 11.2.2 Global Vaccine Adjuvants Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Vaccine Adjuvants Forecast by Type
• 11.8 Global Vaccine Adjuvants Forecast by Application

12 Key Players Analysis

• 12.1 SEPPIC
  • 12.1.1 Company Details
  • 12.1.2 Vaccine Adjuvants Product Offered
  • 12.1.3 SEPPIC Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 SEPPIC News
• 12.2 SDA BIO
  • 12.2.1 Company Details
  • 12.2.2 Vaccine Adjuvants Product Offered
  • 12.2.3 SDA BIO Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 SDA BIO News
• 12.3 Brenntag Biosector
  • 12.3.1 Company Details
  • 12.3.2 Vaccine Adjuvants Product Offered
  • 12.3.3 Brenntag Biosector Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Brenntag Biosector News
• 12.4 SPI Pharma
  • 12.4.1 Company Details
  • 12.4.2 Vaccine Adjuvants Product Offered
  • 12.4.3 SPI Pharma Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 SPI Pharma News
• 12.5 MVP Laboratories
  • 12.5.1 Company Details
  • 12.5.2 Vaccine Adjuvants Product Offered
  • 12.5.3 MVP Laboratories Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 MVP Laboratories News
• 12.6 Tj Kaiwei
  • 12.6.1 Company Details
  • 12.6.2 Vaccine Adjuvants Product Offered
  • 12.6.3 Tj Kaiwei Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Tj Kaiwei News
• 12.7 Novavax
  • 12.7.1 Company Details
  • 12.7.2 Vaccine Adjuvants Product Offered
  • 12.7.3 Novavax Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 Novavax News
• 12.8 Zhuoyue
  • 12.8.1 Company Details
  • 12.8.2 Vaccine Adjuvants Product Offered
  • 12.8.3 Zhuoyue Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 Zhuoyue News
• 12.9 Aphios
  • 12.9.1 Company Details
  • 12.9.2 Vaccine Adjuvants Product Offered
  • 12.9.3 Aphios Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.9.4 Main Business Overview
  • 12.9.5 Aphios News
• 12.10 GSK
  • 12.10.1 Company Details
  • 12.10.2 Vaccine Adjuvants Product Offered
  • 12.10.3 GSK Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.10.4 Main Business Overview
  • 12.10.5 GSK News
• 12.11 CSL Limited
• 12.12 Brenntag Biosector
• 12.13 SEPPIC
• 12.14 SPI Pharma
• 12.15 Novavax
• 12.16 Avanti Polar Lipids
• 12.17 Aphios

13 Research Findings and Conclusion

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
The classification of vaccine adjuvants includes veterinary vaccine adjuvants and human vaccine adjuvants. And the proportion of human vaccine adjuvants in 2016 is about 52.4%. The veterinary vaccine adjuvants in 2015 are about 47.6%.
The classification of Veterinary Vaccine Adjuvants includes Oral, Subcutaneous, Intramuscular and Others. And the proportion of Intramuscular in 2016 is about 56.3%. The Subcutaneous in 2016 is about 29%.
The classification of Human Vaccine Adjuvants includes Oral, Subcutaneous, Intramuscular and Others. And the proportion of Intramuscular in 2016 is about 55.5%. The Subcutaneous in 2016 is about 28.8%.

According to this study, over the next five years the Vaccine Adjuvants market will register a 10.3% CAGR in terms of revenue, the global market size will reach US$ 1010 million by 2024, from US$ 560 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Vaccine Adjuvants business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine Adjuvants market by product type, application, key manufacturers and key regions and countries.

This study considers the Vaccine Adjuvants value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Oral
Subcutaneous
Intramuscular
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Veterinary Vaccine Adjuvants (Research Applications, Commercial Applications)
Human Vaccine Adjuvants (Research Applications, Commercial Applications)

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
SEPPIC
SDA BIO
Brenntag Biosector
SPI Pharma
MVP Laboratories
Tj Kaiwei
Novavax
Zhuoyue
Aphios
GSK
CSL Limited
Brenntag Biosector
SEPPIC
SPI Pharma
Novavax
Avanti Polar Lipids
Aphios

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Vaccine Adjuvants consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Vaccine Adjuvants market by identifying its various subsegments.
Focuses on the key global Vaccine Adjuvants manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Vaccine Adjuvants with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Vaccine Adjuvants submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.